BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis
Grazia Maria Vernaci(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Conte PierFranco, S. Manfrin(University of Padua), Maria Vittoria Dieci(Istituto Oncologico Veneto), Tania Saibene(Istituti di Ricovero e Cura a Carattere Scientifico), G. Gaia, Federica Miglietta(University of Padua), Martín Arroyo Silvia, Cristina Ghiotto(Istituto Oncologico Veneto)
Cited by 4
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290
Evolution of HER2-low expression from primary to recurrent breast cancer
|npj Breast Cancer|2021|226